Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan H Fox

Showing results (111-120 of 178) with videos related to

Pageof 18
Sort By:
Movement Disorders Clinical Practice|July 21, 2023
A Phase Ib, Double Blind, Randomized Study of Cannabis Oil for Pain in Parkinson's DiseaseDaniel G Di Luca, Gabriela S Gilmour, Conor Fearon, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 17, 2005
A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's diseaseMario van der Stelt, Susan H Fox, Michael Hill, et al.
Plos One|October 3, 2012
The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmosetPhilippe Huot, Tom H Johnston, Michael N Gandy, et al.
Movement Disorders Clinical Practice|July 18, 2022
Periodic Limb Movements while Awake (<i>PLMA</i>) as a Manifestation of Wearing-Off in Parkinson's Disease: A Case Series and Review of the LiteratureSohaila Alshimemeri, Daniel G Di Luca, Diana A Olszewska, et al.
Behavioural Pharmacology|October 12, 2014
L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned ratPhilippe Huot, Tom H Johnston, James B Koprich, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 2, 2008
The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's diseaseNaomi P Visanji, Rob M A de Bie, Tom H Johnston, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 15, 2010
Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinationsPhilippe Huot, Tom H Johnston, Tayyeba Darr, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 16, 2012
Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's diseasePhilippe Huot, Tom H Johnston, Naomi P Visanji, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 24, 2018
International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's diseaseSusan H Fox, Regina Katzenschlager, Shen-Yang Lim, et al.
Parkinsonism & Related Disorders|October 7, 2015
What is a clinically important change in the Unified Dyskinesia Rating Scale in Parkinson's disease?Tiago A Mestre, Isabelle Beaulieu-Boire, Camila C Aquino, et al.
Pageof 18

Showing results (111-120 of 178) with videos related to

Sort By:
Pageof 18
Movement Disorders Clinical Practice|July 21, 2023
A Phase Ib, Double Blind, Randomized Study of Cannabis Oil for Pain in Parkinson's DiseaseDaniel G Di Luca, Gabriela S Gilmour, Conor Fearon, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 17, 2005
A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's diseaseMario van der Stelt, Susan H Fox, Michael Hill, et al.
Plos One|October 3, 2012
The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmosetPhilippe Huot, Tom H Johnston, Michael N Gandy, et al.
Movement Disorders Clinical Practice|July 18, 2022
Periodic Limb Movements while Awake (<i>PLMA</i>) as a Manifestation of Wearing-Off in Parkinson's Disease: A Case Series and Review of the LiteratureSohaila Alshimemeri, Daniel G Di Luca, Diana A Olszewska, et al.
Behavioural Pharmacology|October 12, 2014
L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned ratPhilippe Huot, Tom H Johnston, James B Koprich, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 2, 2008
The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's diseaseNaomi P Visanji, Rob M A de Bie, Tom H Johnston, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 15, 2010
Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinationsPhilippe Huot, Tom H Johnston, Tayyeba Darr, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 16, 2012
Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's diseasePhilippe Huot, Tom H Johnston, Naomi P Visanji, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 24, 2018
International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's diseaseSusan H Fox, Regina Katzenschlager, Shen-Yang Lim, et al.
Parkinsonism & Related Disorders|October 7, 2015
What is a clinically important change in the Unified Dyskinesia Rating Scale in Parkinson's disease?Tiago A Mestre, Isabelle Beaulieu-Boire, Camila C Aquino, et al.
Pageof 18